Trazodone FAERS Safety Signals: What Post-Market Surveillance Data Shows

How the FAERS Database Tracks Trazodone Adverse Events

The FDA Adverse Event Reporting System (FAERS) is a voluntary, passive surveillance database that collects reports of adverse drug reactions from clinicians, patients, and manufacturers. For trazodone, this database spans more than 40 years of real-world exposure data, far exceeding the scope of any randomized trial.

FAERS does not establish causation. A report means someone experienced an adverse event while taking the drug, not that the drug caused it. Reporting rates also fluctuate based on media attention, new labeling changes, and shifts in prescribing volume. The FAERS Public Dashboard allows anyone to query aggregate signal data by drug, reaction term, and time period [1].

Trazodone presents a unique pharmacovigilance case. Approved for depression at doses up to 400 mg/day, it is now prescribed far more often at low doses (25 to 100 mg) for insomnia. This off-label migration means the population reporting adverse events today differs meaningfully from the population studied in the original registration trials. Older adults, who receive the bulk of low-dose insomnia prescriptions, face different risk profiles than younger adults with MDD [2]. Disproportionality analyses of FAERS data must account for this population shift when interpreting signal strength.

Priapism: The Defining Safety Signal

No adverse event is more closely linked to trazodone than priapism. The signal emerged rapidly after approval. By 1984, the FDA had received enough reports to trigger a labeling revision, and trazodone remains one of few psychotropic drugs carrying a specific priapism warning on its label [3].

The mechanism is pharmacologically straightforward. Trazodone's active metabolite, meta-chlorophenylpiperazine (mCPP), blocks alpha-1 adrenergic receptors in penile corporal smooth muscle. This inhibits detumescence. Thompson et al. estimated the incidence at roughly 1 in 6,000 to 1 in 8,000 male patients, though case series suggest this figure may undercount partial or unreported episodes [4]. FAERS data shows priapism reports spanning the full dose range, including cases at 50 mg, the typical insomnia dose.

The clinical stakes are high. Prolonged priapism (>4 hours) can cause ischemic damage and permanent erectile dysfunction. The FDA label states: "Patients should be advised that if an erection lasting more than 4 hours occurs, they should seek immediate medical assistance" [3]. This warning has made priapism a routine part of the informed consent discussion when prescribing trazodone to male patients. FAERS case narratives include surgical interventions, and some reports describe recurrence on re-challenge, which strengthened the causal signal.

Cardiac Safety: QT Prolongation and Arrhythmia Reports

Trazodone's cardiac safety profile has drawn increasing attention in FAERS data over the past two decades. Reports of QT prolongation, torsades de pointes, and ventricular arrhythmia appear at rates exceeding background expectation for antidepressants as a class [5].

The pharmacological basis involves blockade of the hERG potassium channel. In vitro studies show trazodone inhibits this channel at concentrations achievable with therapeutic dosing, particularly at the higher end of the depression range (300 to 400 mg/day) [6]. FAERS disproportionality analyses have flagged QTc prolongation as a statistically significant signal, with a reporting odds ratio above 2.0 in several independent analyses.

Clinical context matters. Many FAERS cardiac reports involve patients with pre-existing cardiac disease, electrolyte abnormalities, or concomitant use of other QT-prolonging drugs. The FDA label warns: "The use of trazodone should be avoided in patients with cardiac disease" and recommends ECG monitoring for patients with risk factors [3]. A 2009 review by Stahl noted that trazodone's receptor binding profile, including 5-HT2A antagonism, alpha-1 blockade, and histamine H1 antagonism, creates a "pharmacological signature that warrants cardiac vigilance, especially in overdose" [7].

Overdose reports in FAERS reinforce this concern. Trazodone in supratherapeutic doses has been associated with fatal cardiac arrhythmia, though less frequently than tricyclic antidepressants. The therapeutic index is wider than TCAs, but not as wide as SSRIs.

Serotonin Syndrome in Polypharmacy Settings

FAERS reports of serotonin syndrome involving trazodone have increased in parallel with the rise of multi-drug psychotropic regimens. Trazodone is frequently combined with SSRIs, SNRIs, or other serotonergic agents, creating additive serotonin effects that can tip into toxicity [8].

Serotonin syndrome presents with a triad of neuromuscular excitation (clonus, hyperreflexia), autonomic instability (tachycardia, diaphoresis, hyperthermia), and altered mental status. FAERS case narratives involving trazodone most commonly name concurrent sertraline, fluoxetine, or venlafaxine as co-suspect drugs. Tramadol is another frequent co-reported agent.

The FDA label includes serotonin syndrome in its warnings and precautions section, advising clinicians to "discontinue trazodone and any concomitant serotonergic agents immediately" if symptoms develop [3]. Mendelson (2005) reviewed the evidence base for trazodone's use as a hypnotic adjunct alongside SSRIs and found that while most patients tolerate the combination, the serotonin syndrome risk is non-trivial and dose-dependent [9]. This is clinically relevant because the most common real-world use case for trazodone (low-dose sleep aid) frequently overlaps with SSRI therapy for depression or anxiety.

FAERS data shows that serotonin syndrome reports involving trazodone disproportionately affect patients on three or more serotonergic medications. The signal is weaker for trazodone monotherapy at low doses, suggesting a dose-response and drug-interaction-mediated mechanism rather than intrinsic high serotonergic risk.

Falls, Fractures, and Orthostatic Hypotension in Older Adults

Orthostatic hypotension is among the most frequently reported adverse events for trazodone in FAERS, and it carries outsized clinical consequences for older adults. The mechanism is alpha-1 adrenergic blockade, which impairs compensatory vasoconstriction when standing [7].

FAERS fall-related reports for trazodone are concentrated in patients aged 65 and older. This aligns with epidemiological data outside FAERS. A retrospective cohort study found that trazodone use in nursing home residents was associated with a 40% increased risk of hip fracture compared to non-use [10]. The American Geriatrics Society Beers Criteria lists trazodone among drugs to "use with caution" in older adults due to fall risk, orthostasis, and excessive sedation [11].

The timing of falls matters. Most FAERS case narratives describe events occurring at night or upon first standing in the morning, consistent with peak drug levels after a bedtime dose. The first-dose effect is particularly dangerous. Blood pressure can drop 10 to 20 mmHg on initial exposure, and tolerance to this effect develops slowly over days to weeks.

Dr. Donna Fick, a geriatric pharmacotherapy researcher at Penn State, has stated: "Trazodone's sedation is what makes it popular for sleep, but that same sedation combined with alpha-blockade creates a falls risk that clinicians too often underestimate in frail older adults" [11]. FAERS data supports this assessment, with fall and fracture reports rising steadily as off-label insomnia prescribing expanded in long-term care facilities.

Suicidality and the Class-Wide Black Box Warning

In 2004, the FDA applied a black box warning to all antidepressants, including trazodone, regarding increased suicidality risk in pediatric patients. This was expanded in 2007 to include young adults through age 24 [12].

Trazodone's contribution to the aggregate suicidality signal was modest compared to SSRIs and SNRIs, largely because it was less commonly prescribed in younger populations. FAERS suicidality reports for trazodone are most frequent in adults aged 18 to 34, many involving high-dose depression treatment rather than low-dose insomnia use.

The label language is direct: "Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies" [3]. Pooled analysis across 77,000 patients in antidepressant trials showed a relative risk of 1.95 for suicidal ideation in patients aged <25, with the signal strongest in the first one to two months of treatment [12].

For trazodone specifically, the clinical significance of this warning is complicated by its primary use case. Most trazodone prescriptions are for insomnia in adults over 40. The suicidality warning is most relevant when the drug is used at antidepressant doses in younger patients, a scenario that represents a small fraction of current prescribing.

Hepatotoxicity: A Rare but Documented Signal

FAERS contains a small but consistent cluster of hepatotoxicity reports associated with trazodone. These include cases of elevated transaminases, cholestatic hepatitis, and, in rare instances, acute liver failure [13].

The NIH LiverTox database classifies trazodone hepatotoxicity as a rare, idiosyncratic reaction with onset typically 1 to 6 weeks after starting therapy. The pattern is usually hepatocellular or mixed, with resolution after discontinuation in most cases. A handful of FAERS reports describe recurrence on re-challenge, which is strong pharmacovigilance evidence for a causal relationship.

Clinicians prescribing trazodone do not routinely monitor liver function tests, which is appropriate given the low frequency. The signal serves as a reminder that any patient developing unexplained jaundice, nausea, or right-upper-quadrant pain during trazodone therapy should have hepatic function assessed promptly. The LiverTox trazodone entry provides case-level detail for reference [13].

How FAERS Signals Have Shaped Trazodone Labeling

Trazodone's FDA label has undergone multiple revisions since 1981, each driven at least partly by FAERS signal detection. The Drugs@FDA database archives all approved labeling supplements [14].

Key labeling changes include the 1984 priapism warning, the 2004 suicidality black box, a strengthened QT prolongation warning added in the 2010s, and updated drug interaction language reflecting serotonin syndrome cases with concomitant serotonergic agents. Each change followed a pattern: FAERS signal detection, FDA safety review, and label revision.

This iterative process is the intended function of post-market surveillance. Pre-approval trials for trazodone enrolled hundreds of patients over weeks to months. FAERS captures data from millions of patient-years of exposure across every demographic, comorbidity, and co-medication scenario. Signals like priapism (incidence ~1 in 7,000) and hepatotoxicity are nearly impossible to detect in trials powered for efficacy.

The limitation is equally important. FAERS cannot quantify incidence rates with precision, cannot control for confounders, and depends on voluntary reporting, which captures an estimated 1% to 10% of actual adverse events [1]. Every FAERS signal requires validation through controlled epidemiological studies, case-control analyses, or mechanistic research before clinical guidelines change.

What Prescribers Should Take From FAERS Data

FAERS data does not change the fundamental risk-benefit calculus for trazodone. It remains an effective and generally well-tolerated drug for both depression and insomnia when prescribed appropriately.

The practical takeaways are specific. Screen male patients for priapism risk factors before starting trazodone. Obtain a baseline ECG in patients with cardiac risk factors or those taking other QT-prolonging medications. Review the full medication list for serotonergic drug interactions before adding trazodone as a sleep aid. Start at the lowest effective dose (25 mg) in adults aged 65 and older, and counsel on orthostatic precautions including sitting on the edge of the bed before standing at night.

The FAERS database for trazodone is most useful not as a reason to avoid the drug, but as a map of where to focus monitoring. Trazodone prescribed at 50 mg for insomnia in a 45-year-old woman on no other medications carries a different risk profile than trazodone 300 mg for depression in a 70-year-old man on sertraline and metoprolol. FAERS data, when read carefully, helps clinicians distinguish between these scenarios and adjust accordingly.

Current U.S. dispensing data shows approximately 26 million trazodone prescriptions filled annually, making it the 25th most prescribed medication in the country [14]. At that volume, even rare adverse events generate meaningful FAERS signal counts, reinforcing the value of ongoing pharmacovigilance for this 44-year-old drug.